Accord Healthcare, SLU Pharmaceutical Import Profile — Spain (DGFT 2022–2026)

Name: Accord Healthcare, SLU Pharmaceutical Import Records from India — 7 Products, $1.7M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Accord Healthcare, SLU — Pharmaceutical Importer Profile (2026) | 7 Products, $1.7M Trade | TransData Nexus

Accord Healthcare, SLU

Pharmaceutical Importer · Spain · Cardiovascular Focus · $1.7M Total Trade · DGFT Verified

Accord Healthcare, SLU is a pharmaceutical importer based in Spain with a total trade value of $1.7M across 7 products in 3 therapeutic categories. Based on 97 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Accord Healthcare, SLU sources from 1 verified Indian supplier, with Intas Pharmaceuticals Limited accounting for 100.0% of imports.

Accord Healthcare, SLU — Import Portfolio & Supplier Network

Accord Healthcare, SLU import network — 7 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Accord Healthcare, SLU?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Intas Pharmaceuticals Limited	$2.8M	176	100.0%

Accord Healthcare, SLU sources from 1 verified Indian supplier across 76 distinct formulations. The sourcing is highly concentrated — Intas Pharmaceuticals Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

Formulation	Value	Ships
Pharma drugs & medi: accofil 30mu/0.5ML	$586.2K	12
Pharma drugs & medi propranolol 40MG	$208.4K	23
Pharma drugs & medi propranolol 10MG	$175.2K	16
Pharma drugs & medi irinotecan INJ	$131.8K	12
Pharma drugs & medi strantas(fulv pfs	$123.9K	3
Pharma drugs & medi: pelgraz 6MG/0.6ML	$100.0K	2
Pha.dru & medi, tran(nalt) 50MG 2x14t g1(accord-spain Each film coated tablet contains:naltrexone	$100.0K	3
Pharma drugs & medi fosaprepitant pow	$71.1K	4
Pharma drugs & medi propranolol 10MG 5x10t(accord-spain as per	$63.2K	3
Phr drugs&medi dimethyl fumarat 240MG 4x14c(aco-pp-es Each Gastro-Resistant hardcapsule contains 240 MG	$62.8K	3
Pharma drugs & medi ondansetron	$58.6K	4
Pharma drugs & medi: fosaprepitant pow	$51.6K	2
Pharma drugs & medi cabazitaxel 20MG/ML	$50.0K	1
Pharma drugs & medi pelgraz 6MG/0.6ML	$50.0K	1
Pharma drugs & medi tadalafil 20MG	$50.0K	1

Import Portfolio — Top 7 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Propranolol	Cardiovascular	$870.4K	66	0.8%	7
2	Cytarabine	Advanced Oncology	$245.7K	15	2.3%	13
3	Fluorouracil	Oncology	$182.2K	4	1.5%	11
4	Imatinib	Advanced Oncology	$150.0K	3	0.5%	18
5	Cabazitaxel	Advanced Oncology	$100.0K	2	1.1%	5
6	Topotecan	Advanced Oncology	$82.1K	4	2.2%	8
7	Fludarabine	Advanced Oncology	$64.5K	3	2.2%	11

Accord Healthcare, SLU imports 7 pharmaceutical products across 3 categories into Spain totaling $1.7M.

Accord Healthcare, SLU — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Accord Healthcare, S.L.U. is a Spanish pharmaceutical company specializing in the commercialization, sale, distribution, importation, and exportation of medicinal substances, pharmaceutical products, dermatological items, and hygiene products. Established in 2009, the company began actively marketing its products in September 2010, offering a broad range of generic medicines to healthcare professionals and patients across Spain.

As a subsidiary of Intas Pharmaceuticals Limited, Accord Healthcare, S.L.U. benefits from the extensive resources and expertise of its parent company. This affiliation enables Accord to leverage Intas's global manufacturing capabilities, including six EU GMP-approved manufacturing plants and an EU packing site near Cambridge, UK, providing some of the largest production capacities in the world.

Headquartered at the World Trade Center in Barcelona, Spain, Accord Healthcare, S.L.U. serves as a key player in the Spanish pharmaceutical distribution network. Its operations encompass the importation and distribution of a diverse portfolio of pharmaceutical formulations, catering to various therapeutic areas and meeting the needs of both public and private hospital groups, as well as wholesalers.

2Distribution Network

Accord Healthcare, S.L.U. operates from its headquarters located at the World Trade Center in Barcelona, Spain. While specific details regarding additional warehouse locations and logistics capabilities are not publicly disclosed, the company's affiliation with Intas Pharmaceuticals Limited suggests access to a robust distribution network. Intas's extensive manufacturing and packing facilities, including six EU GMP-approved plants and an EU packing site near Cambridge, UK, provide substantial production capacities, facilitating efficient distribution of pharmaceutical products across Spain and potentially to other European markets.

3Industry Role

Accord Healthcare, S.L.U. functions as a pharmaceutical importer and distributor within Spain's supply chain. The company imports finished pharmaceutical formulations from India, focusing on generic medicines across various therapeutic areas. By leveraging its parent company's manufacturing capabilities and its own distribution network, Accord Healthcare, S.L.U. plays a significant role in ensuring the availability of affordable and essential medicines to healthcare providers and patients in Spain.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Accord Healthcare, SLU

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Accord Healthcare, S.L.U. demonstrates a high degree of supplier concentration, sourcing all its pharmaceutical imports from a single supplier: Intas Pharmaceuticals Limited. This exclusive sourcing strategy has resulted in a total import value of $1.7 million USD over 97 shipments, encompassing 76 unique formulations across seven products and three therapeutic categories. The top five imported products—Propranolol, Cytarabine, Fluorouracil, Imatinib, and Cabazitaxel—account for 91.4% of the total import value, indicating a strong reliance on these specific formulations.

While this concentrated sourcing approach may offer benefits such as streamlined procurement processes and potentially favorable pricing, it also introduces risks associated with supplier dependency. Any disruptions in Intas Pharmaceuticals Limited's production or supply chain could directly impact Accord Healthcare, S.L.U.'s ability to meet market demand. The stability of this relationship is crucial, and ongoing assessments of supplier performance and contingency planning are advisable to mitigate potential risks.

2Supply Chain Resilience

Accord Healthcare, S.L.U.'s supply chain resilience is closely tied to its exclusive partnership with Intas Pharmaceuticals Limited. The company's importation of finished pharmaceutical formulations from India suggests a reliance on international shipping routes, which may expose the supply chain to potential disruptions such as geopolitical tensions, logistical challenges, or regulatory changes.

Importing Pharmaceuticals into Spain — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Spain

1Regulatory Authority & Framework

In Spain, the Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) is the primary regulatory authority overseeing the pharmaceutical sector. AEMPS is responsible for ensuring the quality, safety, and efficacy of medicinal products, including those imported from non-EU countries.

Key legislation governing pharmaceutical imports into Spain includes the Spanish Medicines Act and the Royal Decree on the Importation of Medicinal Products. These regulations outline the requirements for marketing authorization, import licensing, and compliance with Good Manufacturing Practice (GMP) standards. For Indian generics to be marketed in Spain, they must undergo a centralized marketing authorization procedure through the European Medicines Agency (EMA), ensuring compliance with EU standards.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products in Spain mandate that all imported medicines possess a valid marketing authorization issued by AEMPS. Additionally, imported products must be manufactured in facilities that comply with EU GMP standards, as recognized by AEMPS.

For Indian exporters, obtaining EU GMP certification is essential to meet these import licensing requirements. This certification ensures that manufacturing processes adhere to the stringent quality standards set by the EU, facilitating smoother market entry and acceptance within Spain.

Accord Healthcare, SLU — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Accord Healthcare, S.L.U.'s focus on importing generic medicines in therapeutic areas such as oncology, immunosuppressants, central nervous system (CNS) treatments, anti-infectives, and gastroenterology reflects a strategic alignment with prevalent health concerns in Spain. The high import values of products like Propranolol, Cytarabine, Fluorouracil, Imatinib, and Cabazitaxel indicate strong market demand in these categories.

This product strategy enables Accord Healthcare, S.L.U. to address critical healthcare needs, providing affordable alternatives to branded medications and enhancing patient access to essential treatments.

2Sourcing Profile

Accord Healthcare, S.L.U. primarily sources generic pharmaceutical formulations from India, leveraging the country's robust manufacturing capabilities and cost-effective production. The company's exclusive partnership with Intas Pharmaceuticals Limited underscores a strategic sourcing approach focused on quality and reliability.

This sourcing strategy allows Accord Healthcare, S.L.U. to offer a diverse portfolio of generic medicines, catering to various therapeutic areas and meeting the needs of the Spanish market.

3Market Positioning

Seller's Guide — How to Become a Supplier to Accord Healthcare, SLU

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to collaborate with Accord Healthcare, S.L.U. By offering high-quality generic formulations that meet EU GMP standards, Indian exporters can position themselves as viable partners. Diversifying Accord Healthcare, S.L.U.'s supplier base could enhance supply chain resilience and provide Indian exporters with a stable market for their products.

Identifying gaps in Accord Healthcare, S.L.U.'s current sourcing, such as unmet therapeutic needs or emerging market trends, can further inform strategic partnerships and product development initiatives.

TransData Nexus Research · Industry procurement practicesMar 2026

Frequently Asked Questions — Accord Healthcare, SLU

What products does Accord Healthcare, SLU import from India?

Accord Healthcare, SLU imports 7 pharmaceutical products across 3 categories. Top imports: Propranolol ($870.4K), Cytarabine ($245.7K), Fluorouracil ($182.2K), Imatinib ($150.0K), Cabazitaxel ($100.0K).

Who supplies pharmaceuticals to Accord Healthcare, SLU from India?

Accord Healthcare, SLU sources from 1 verified Indian suppliers. The primary supplier is Intas Pharmaceuticals Limited (100.0% of imports, $2.8M).

What is Accord Healthcare, SLU's total pharmaceutical import value?

Accord Healthcare, SLU's total pharmaceutical import value from India is $1.7M, based on 97 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Accord Healthcare, SLU focus on?

Accord Healthcare, SLU imports across 3 categories. The largest: Cardiovascular (51.4%), Advanced Oncology (37.9%), Oncology (10.7%).

Get Full Accord Healthcare, SLU Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.